Navigation Links
Venaxis' APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
Date:7/15/2013

CASTLE ROCK, Colo., July 15, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced that the external Data and Safety Monitoring Board (DSMB) created as part of the Company's pivotal clinical trial for the APPY1 Test has recommended continuation of the pivotal clinical trial, based upon completion of the first of two futility analyses included in the clinical trial design.  Venaxis will host a conference call and webcast tomorrow morning, July 16, 2013, at 8:30 a.m. ET, to discuss the DSMB's recommendation and to provide a general corporate update.

The futility analysis, which consisted of an independent review of the validity, integrity, and clinical and scientific relevance of the ongoing study, was performed on the first 579 patients to complete the study.  The study will enroll a total of 2,000 evaluable patients.  The next and final futility analysis will include data from the first approximately 1,200 patients.

Steve Lundy, President and CEO of Venaxis, stated, "While the results of the study remain blinded to Venaxis, we are very pleased that the pivotal clinical trial has passed this important interim analysis step successfully.  The APPY1 Test performed very well in the previous 500-patient study, so we regard this outcome as encouraging and we look forward to the next assessment.  Enrollment in the pivotal study continues to accelerate as our recently initiated sites ramp-up their enrollment.  We expect to complete enrollment for the pivotal study by the end of 2013, and if the results are positive, file for FDA clearance in the first quarter 2014.  In the meantime, we continue to execute
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Venaxis Announces Pricing of Offering of Common Stock and Warrants
2. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
3. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
4. Eastern Clinical Trials Russia CRO Passes EMA Inspection
5. Legendary Author And Screenwriter Nora Ephron Passes Away At 71; Solar Cigarette Pays Tribute To Such A Rare Talent
6. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
7. Free Expo-Hall Passes for ATA 2012
8. Accuray Surpasses 600 Installations Globally
9. Unisense FertiliTech to Present Large Scale Time-lapse Data Analysis to Improve IVF Treatment
10. New Approaches in Immunogenicity Assessment Using the New SQiDlite™ System: Case Study Analysis, New Life Science Webinar Hosted by Xtalks
11. Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... in Brazil and ... restrictions. The uptake of several newly approved agents, ... for this indication and the launch of emerging ... asthma markets. In particular, the emerging IL-5 inhibitors ...
(Date:8/21/2014)... Pursuit Solutions ( http://www.pursuit-solutions.com ), a ... for Life Sciences sales and marketing organizations, announced ... Commercial Sales Models” by Peter Robinson, co-founder and ... examines some innovative models used to improve sales ... the pharmaceutical market. Robinson grades the industry on ...
(Date:8/20/2014)... Clintrax Global, Inc., a worldwide provider ... Raleigh, NC , recently announced the addition ... of Administration. As Vice President ... including their alignment with company objectives and policies.  ... an HR executive, specializing in needs assessments, customer ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Clintrax Global, Inc. Announces Addition to Executive Team 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3
... announced,the appointment of David J. Mazzo, Ph.D., as President ... to Regado almost 25,years of experience in the pharmaceutical ... Dr. Mazzo also has served as,President and CEO of ... Co., Ltd. of Japan, a member of the Roche ...
... In Single Port Access Surgery Achieves Another Milestone, ... a pioneer in,the rapidly emerging Single Port Access ... has been granted a CE Mark for its ... laparoscopic surgery, the surgeon makes four to six,"keyhole" ...
... Clinicians to Monitor Activity of New ... Class of Potent Antiretroviral Drugs, SOUTH ... MGRM ) today announced the launch of its,PhenoSense(R) Integrase assay, ... the susceptibility of,HIV to a new and potent class of ...
Cached Biology Technology:David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO 2Autonomy(TM) Lapro-Angle(TM) Articulating Laparoscopic Instruments Granted CE Mark 2Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 2Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 3Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 4Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors 5
(Date:8/20/2014)... are visible in in this image of the Para ... these were most likely intentionally set in order to ... forest or stand of trees where the land is ... include conversion of forestland to farms, ranches, or urban ... green of the Amazon Rainforest in the middle of ...
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
(Date:8/20/2014)... Tech,s Wu Feng has built upon a National Science ... the Cloud" program, and synergistically complemented it with subsequent ... Air Force on "big computing" for mini-drones and a ... of Health on "big data" for the life sciences. ... from each grant, he was able to tell a ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4
... , July 14 Orbel,s Hi-Flex™ Fabric over Foam ... and wrapped with a durable high performance copper-nickel plated conductive fabric. ... low compression forces making them ideal for shielding seams, doors and ... , , ...
... U.S. Department of Energy,s Savannah River National Laboratory ... State University to decrease mold growth in flooded ... Funded by the Department of Homeland Security (DHS) ... State University asked SRNL and Tuskegee University to ...
... more blood banks to adopt so-called "extended blood group ... and recipients. Their report on a new, automated genetic ... appears in ACS, Analytical Chemistry , a semi-monthly ... most blood banks still use a century-old blood approach ...
Cached Biology News:Orbel Expands Fabric over Foam Gasket Product Line 2SRNL works to decrease hazards from mold in water damaged homes 2
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... collection of phage display libraries, human ... and mouse tissues. All cDNA libraries ... size of cDNA inserts has been ... 1000bp by gel electrophoresis of DNA ...
... stability and convenience from the former kit #17295. ... this problem but also produced some advantages as ... of HRP conjugated antibody from lyophilized product to ... stability of the conjugate has improved so that ...
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
Biology Products: